Singapore-based firm on track to commercialise cancer drug
Tessa Therapeutics teams up with California institute to run cancer-therapy trial, commercial launch expected in 2020
Singapore
SCIENTISTS are now a step closer to turning cancer patients' own immune cells (T-cells) against the tumours in their bodies - and possibly finding a cure for the dreaded disease.
A Singapore-based biotechnology firm has emerged ahead of the very crowded research field of T-cell immunotherapy, by conducting the world's first US Food and Drug Administration (FDA) Phase Three cancer T-cell therapy trial involving a number of hospitals and treatment centres across the world.
This means Tessa Therapeutics will produce the world's first commercial T-cell therapy treatment for solid tumours.
Tessa announced last week that it has set up a multi-year strategic alliance with …
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
International
Norway's wealth fund posts US$109 billion Q1 profit as tech stocks soar
Norway wealth fund backs NatWest plan to buy more state-owned stock
Japanese firms agree on 5.2% pay raise, biggest union group Rengo says
Singapore ready to harvest economic opportunities in the Philippines: Vivian Balakrishnan
Australia regulator flags surge in company insolvencies to 11-year high
Elon Musk stakes fortune on cult following who made him rich